Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CYDY NASDAQ:KURA NASDAQ:MCRB NASDAQ:MDGL NASDAQ:MGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.30+7.1%$0.30$0.10▼$0.49$377.15M1.422.70 million shs2.78 million shsKURAKura Oncology$8.35+1.7%$6.96$5.41▼$21.40$724.76M0.191.48 million shs1.32 million shsMCRBSeres Therapeutics$17.40+10.9%$15.92$6.53▼$24.67$152.25M0.15116,035 shs154,360 shsMDGLMadrigal Pharmaceuticals$427.05+0.3%$366.84$200.63▼$457.16$9.48B-1.02377,399 shs243,387 shsMGNXMacroGenics$1.47-5.8%$1.63$0.99▼$5.10$92.92M1.63925,824 shs1.05 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn-2.03%-24.69%+1.82%-17.79%+86.67%KURAKura Oncology+0.24%+0.86%+11.85%+32.42%-60.68%MCRBSeres Therapeutics-1.38%-31.33%-5.99%+114.34%-21.49%MDGLMadrigal Pharmaceuticals-1.53%-6.21%+15.08%+52.22%+76.01%MGNXMacroGenics-1.89%-11.36%-1.27%+13.87%-57.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.30+7.1%$0.30$0.10▼$0.49$377.15M1.422.70 million shs2.78 million shsKURAKura Oncology$8.35+1.7%$6.96$5.41▼$21.40$724.76M0.191.48 million shs1.32 million shsMCRBSeres Therapeutics$17.40+10.9%$15.92$6.53▼$24.67$152.25M0.15116,035 shs154,360 shsMDGLMadrigal Pharmaceuticals$427.05+0.3%$366.84$200.63▼$457.16$9.48B-1.02377,399 shs243,387 shsMGNXMacroGenics$1.47-5.8%$1.63$0.99▼$5.10$92.92M1.63925,824 shs1.05 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn-2.03%-24.69%+1.82%-17.79%+86.67%KURAKura Oncology+0.24%+0.86%+11.85%+32.42%-60.68%MCRBSeres Therapeutics-1.38%-31.33%-5.99%+114.34%-21.49%MDGLMadrigal Pharmaceuticals-1.53%-6.21%+15.08%+52.22%+76.01%MGNXMacroGenics-1.89%-11.36%-1.27%+13.87%-57.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYDYCytoDyn 0.00N/AN/AN/AKURAKura Oncology 2.80Moderate Buy$24.10188.62% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67323.37% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$483.3813.19% UpsideMGNXMacroGenics 2.33Hold$3.60144.90% UpsideCurrent Analyst Ratings BreakdownLatest MDGL, MGNX, MCRB, KURA, and CYDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$428.00 ➝ $526.009/4/2025KURAKura OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral9/4/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$500.008/26/2025MDGLMadrigal PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/26/2025MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$390.00 ➝ $554.008/20/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$483.00 ➝ $485.008/15/2025MGNXMacroGenicsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $5.008/12/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$458.00 ➝ $523.008/11/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$28.00 ➝ $24.008/6/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$420.00 ➝ $428.006/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYDYCytoDynN/AN/AN/AN/A($0.08) per shareN/AKURAKura Oncology$83.28M8.70N/AN/A$5.32 per share1.57MCRBSeres Therapeutics$126.32M1.21N/AN/A$1.61 per share10.81MDGLMadrigal Pharmaceuticals$180.13M52.63N/AN/A$34.59 per share12.35MGNXMacroGenics$149.96M0.62N/AN/A$1.85 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYDYCytoDyn$3.74M$0.0130.03∞N/AN/AN/A-4.40%10/15/2025 (Estimated)KURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%11/6/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.57N/AN/AN/A-21.99%-40.24%-14.62%11/4/2025 (Estimated)Latest MDGL, MGNX, MCRB, KURA, and CYDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGNXMacroGenics-$0.59-$0.57+$0.02-$0.57$28.06 million$22.24 million8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 million7/25/2025Q4 2025CYDYCytoDynN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYDYCytoDynN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYDYCytoDynN/A0.250.25KURAKura Oncology0.026.166.16MCRBSeres TherapeuticsN/A1.571.57MDGLMadrigal Pharmaceuticals0.175.114.78MGNXMacroGenicsN/A5.265.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYDYCytoDyn5.06%KURAKura OncologyN/AMCRBSeres Therapeutics59.34%MDGLMadrigal Pharmaceuticals98.50%MGNXMacroGenics96.89%Insider OwnershipCompanyInsider OwnershipCYDYCytoDyn0.54%KURAKura Oncology6.40%MCRBSeres Therapeutics4.70%MDGLMadrigal Pharmaceuticals21.50%MGNXMacroGenics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYDYCytoDyn201.26 billion1.25 billionNot OptionableKURAKura Oncology13086.80 million81.24 millionOptionableMCRBSeres Therapeutics3308.75 million8.34 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableMGNXMacroGenics43063.21 million54.99 millionOptionableMDGL, MGNX, MCRB, KURA, and CYDY HeadlinesRecent News About These CompaniesBrokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $3.60September 15 at 2:13 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14 at 2:13 AM | marketbeat.com198,470 Shares in MacroGenics, Inc. $MGNX Acquired by Nuveen LLCSeptember 8, 2025 | marketbeat.comMacroGenics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comMacroGenics (NASDAQ:MGNX) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?August 28, 2025 | marketbeat.comWilliam Heiden Bought 909% More Shares In MacroGenicsAugust 23, 2025 | finance.yahoo.comWilliam Heiden Bought 909% More Shares In MacroGenicsAugust 23, 2025 | finance.yahoo.comStifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)August 23, 2025 | theglobeandmail.comMacroGenics (NASDAQ:MGNX) Director William Heiden Acquires 49,500 SharesAugust 22, 2025 | insidertrades.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 19, 2025 | marketbeat.comCitizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)August 17, 2025 | theglobeandmail.comMacroGenics (NASDAQ:MGNX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAugust 17, 2025 | marketbeat.comLeerink Partners Lowers MacroGenics (NASDAQ:MGNX) Price Target to $5.00August 17, 2025 | marketbeat.comMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic PrioritiesAugust 16, 2025 | uk.finance.yahoo.comMacroGenics Revenue Doubles in Q2August 16, 2025 | theglobeandmail.comMacroGenics price target lowered to $5 from $8 at LeerinkAugust 16, 2025 | msn.comMacroGenics Inc. Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comMacroGenics reports Q2 EPS (57c), consensus (38c)August 14, 2025 | msn.comMacroGenics (MGNX) Reports Q2 Loss, Tops Revenue EstimatesAugust 14, 2025 | zacks.comMacroGenics: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comTMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic PrioritiesAugust 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDGL, MGNX, MCRB, KURA, and CYDY Company DescriptionsCytoDyn OTCMKTS:CYDY$0.30 +0.02 (+7.14%) As of 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Kura Oncology NASDAQ:KURA$8.35 +0.14 (+1.71%) Closing price 04:00 PM EasternExtended Trading$8.43 +0.08 (+0.90%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Seres Therapeutics NASDAQ:MCRB$17.40 +1.71 (+10.90%) Closing price 04:00 PM EasternExtended Trading$17.46 +0.06 (+0.34%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Madrigal Pharmaceuticals NASDAQ:MDGL$427.05 +1.45 (+0.34%) Closing price 04:00 PM EasternExtended Trading$426.39 -0.66 (-0.15%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.MacroGenics NASDAQ:MGNX$1.47 -0.09 (-5.77%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.05 (+3.40%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
